Search Results
Aug 11, 2026, 20:45 ET New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer (LA/mBC) with PIK3CA/AKT1/PTEN alterations, following recurrence or progression on or after endocrine therapy(-ies) (with or without a CDK4/6 inhibitor). The NDA is
More news about: Laekna
Aug 04, 2026, 07:00 ET Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.
More news about: Labcorp
Aug 03, 2026, 07:00 ET Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
that high TROP2 H-scores and low PTEN H-scores predicted patient response in preclinical studies. These findings were further correlated with longer Progression Free Survival (PFS) in clinical studies, specifically for NSCLC patients with TROP2 H-scores above 100 and PTEN H-scores below 100. This data underscores
More news about: Genprex, Inc.
Jul 30, 2026, 06:50 ET Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence.Expanded nationwide access to Roche's FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca's targeted therapy
More news about: Labcorp Holdings Inc
Jul 14, 2026, 08:30 ET Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve
More news about: Caris Life Sciences
May 26, 2026, 17:12 ET 美納里尼集團於 2026 年美國臨床腫瘤學會 (ASCO) 年會上發佈新數據
大會將發表一項第 1/2 期 ELEVATE 研究的全新數據，探索埃拉司群與卡帕塞替尼聯合療法，應用於 ER+/HER2-（雌激素受體陽性/第 2 型人類表皮生長因子受體陰性）且伴隨 PI3K/AKT/PTEN 通路變異的轉移性乳癌患者時的安全性及初步療效。 會上將分享更多關於埃拉司群於晚期治療階段中的聯合療法研究詳情，包括：ADELA（與依維莫司 (everolimus) 聯合治療的關鍵第 3 期研究）；ELECTRA（與阿貝馬西利 (abemaciclib) 聯合治療腦轉移患者的第 1b/2 期研究）；以及
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 16:45 ET Menarini Group annuncia nuovi dati alla riunione annuale dell'American Society of Clinical Oncology (ASCO) 2026
preliminare di elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) alterato dalla via ER+/HER2- PI3K/AKT/PTEN- dallo studio ELEVATE di fase 1/2. Ulteriori dettagli sugli studi in corso su elacestrant in combinazione, nel contesto avanzato, saranno condivisi:
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 08:10 ET Menarini Group、American Society of Clinical Oncology (ASCO)の2026年年次総会で新データを発表
ER+/HER2- PI3K/AKT/PTEN- 経路を変化させた転移性乳癌（mBC）患者におけるエラセストラント とカピバセルチブ の併用療法 の安全性と予備的有効性を探る新たなデータが、第 1/2 相ELEVATE 試験より発表されます。現在進行中のエラセストラント併用療法の詳細について、ADELA（エベロリムスとの極めて重要な第3相併
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 08:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
levels of PTEN protein in lung cancer cell lines as correlating with response (AACR 2026). Tumor tissue from patients in clinical trials with quaratusugene ozeplasmid were evaluated for Trop-2 and PTEN protein expression.Monoclonal antibodies against Trop-2 (BSB148 from BioSB) and PTEN (138G6 from
More news about: Genprex, Inc.
May 25, 2026, 11:56 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 새로운 데이터 발표
1/2상 ELEVATE 시험에서 ER+/HER2- PI3K/AKT/PTEN 경로 변이가 있는 전이성 유방암(mBC) 환자를 대상으로 카피바세르팁과 병용한 엘라세스트란트의 안전성 및 예비 유효성을 탐색한 신규 데이터가 발표된다. 진행성 환경에서 엘라세스트란트 병용요법을 평가하는 진행 중인 시험들에 대한 추가 세부 내용도 공유될 예정이다. 여기에는
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
preliminar de elacestrant en combinación con capivasertib en pacientes con cáncer de mama metastásico (mBC) con alteraciones en la vía ER+/HER2- PI3K/AKT/PTEN-, provenientes del estudio ELEVATE de fase 1/2. Se compartirán detalles adicionales sobre estudios en curso de elacestrant en combinación con capivasertib
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
werden neue Daten zur Sicherheit und vorläufigen Wirksamkeit von Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER+/HER2- PI3K/AKT/PTEN-verändertem metastasiertem Brustkrebs (mBC) aus der Phase-1/2-Studie ELEVATE vorgestellt. Weitere Einzelheiten zu laufenden Studien über die Kombination
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
l'elacestrant en combinaison avec le capivasertib chez les patientes atteintes d'un cancer du sein métastatique (mBC) altéré par la voie ER+/HER2- PI3K/AKT/PTEN- seront présentées à partir de l'étude de phase 1/2 ELEVATE . Des détails supplémentaires sur les études en cours sur l'association d'elacestrant, dans
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
eficácia preliminar do elacestranto em combinação com capivasertibe em pacientes com câncer de mama metastático (mBC) alterado pela via ER+/HER2- PI3K/AKT/PTEN- do estudo ELEVATE de fase 1/2 serão apresentados. Detalhes adicionais sobre os estudos em andamento do elacestranto em combinação, no cenário avançado,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 07:46 ET El Grupo Menarini anuncia nuevos datos en la Reunión Anual de la Sociedad Estadounidense de Oncología Clínica (asco) 2026
eficacia preliminar de elacestrant en combinación con capivasertib en pacientes con cáncer de mama metastásico (CMM) alterado por la vía ER+/HER2- PI3K/AKT/PTEN- del estudio ELEVATE de fase 1/2. Se compartirán detalles adicionales sobre los estudios en curso de elacestrant en combinación, en el entorno avanzado:
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 06:44 ET Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
New data exploring the safety and preliminary efficacy of elacestrant in combination with capivasertib in patients with ER+/HER2- PI3K/AKT/PTEN- pathway altered metastatic breast cancer (mBC) from the phase 1/2 ELEVATE study will be presented. Additional details on ongoing studies of elacestrant
More news about: Menarini Industrie Farmaceutiche Riunite
Apr 21, 2026, 07:00 ET Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
modern cancer therapies. PTEN (phosphatase and tensin homolog) is a tumor suppressor gene that serves as a multi-functional cancer biomarker for risk assessment, diagnosis and treatment planning in a number of cancers."We are very excited to expand our research of TROP2 and PTEN to better understand
More news about: Genprex, Inc.
Apr 20, 2026, 07:00 ET Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
models showed low expression of TROP2 and high expression of PTEN as potential biomarkers of primary resistance. Overexpression of TROP2 in H1299 and H460 cells increased TUSC2-induced apoptosis. These findings suggest that TROP2 and PTEN may serve as biomarkers to predict TUSC2 response and guide therapeutic
More news about: Genprex, Inc.
Mar 18, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
models showed low expression of TROP2 and high expression of PTEN as potential biomarkers of primary resistance. Overexpression of TROP2 in H1299 and H460 cells increased TUSC2-induced apoptosis. These findings suggest that TROP2 and PTEN may serve as biomarkers to predict TUSC2 response and guide therapeutic
More news about: Genprex, Inc.
Feb 17, 2026, 09:08 ET Autel Donates TS900 Diagnostic Tablet Packages to ASE Accredited Schools Through ASE Education Foundation Partnership
service capabilities. The tablet ships with eight programmable Autel TPMS sensors, the 1-Sensor. The TS900 received both a Motor Top 20 Product Award and PTEN People's Choice Award in the year of its release.This donation marks the launch of Autel Inspires, a long-term initiative within the Autel Cares
More news about: Autel U.S.
Jan 05, 2026, 17:31 ET Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight
expected to perform better in the future, such as AKEEGA (HRR gene-mutated mCSPC), TALZENNA (DDR-deficient mCSPC), TRUQAP (de novo PTEN-deficient mHSPC), and others.Radioligand and PARP Inhibitors Driving Future CSPC Market GrowthThe emergence of radioligand and
More news about: DelveInsight Business Research, LLP
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
#PS1-11-27Poster Session 1. December 10, 2025. 12:30-2:00 PM CSTComprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer-- An Exploratory Analysis of Biomarker Concordance and Co-Occurrence.
More news about: Caris Life Sciences
Nov 04, 2025, 06:45 ET SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance
an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway and (2) leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies
More news about: SOPHiA GENETICS
Sep 22, 2025, 08:00 ET SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network that regulates how cells grow and survive, and its disruption is linked to the development of many cancers, including breast and prostate cancer. The PTEN gene, when altered, can contribute to
More news about: SOPHiA GENETICS
Sep 22, 2025, 08:00 ET SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network that regulates how cells grow and survive, and its disruption is linked to the development of many cancers, including breast and prostate cancer. The PTEN gene, when altered, can contribute to
More news about: SOPHiA GENETICS